My field of study is DNA methylation as a biomarker for gynecological cancers. My clinical PhD project investigates whether DNA methylation as a biomarker in patient-collected urine and vaginal samples can improve risk assessment for women suspected of having endometrial cancer. The goal is faster and gentler risk stratification, ensuring that high-risk women are promptly referred, while low-risk patients can avoid invasive procedures. This can benefit both patients and the healthcare system